ART4 and acute coronary syndrome: Drug induced profound thrombocytopenia [16], a predictor of adverse outcome in patients with acute coronary syndromes, is defined as a decrease in platelet count to below 20,000/mm3 within 24 hours of exposure to the drug and may be associated with the administration of eptifibatide, a glycoprotein antagonist.